Automated Prevention and Control of Epileptic Seizures Using Biochemical And/or Electrical Signal Markers

• US 20130345526A1
• Filed: 03/07/2013
• Published: 12/26/2013
• Est. Priority Date: 06/25/2012
• Status: Abandoned Application

• Current Assignee: Flint Hills Scientific, LLC
• Original Assignee: Flint Hills Scientific, LLC
• Inventors: Osorio, Ivan
• Application Number:
  US13/789,320
• Publication Number:
  US 20130345526A1
• Time in Patent Office: Days
• US Class Current: 600/309
• CPC Class Codes: A61B 5/14503 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/369 Electroencephalography [EEG] devices for psychotechnics A61B5/16
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: A61B 5/7282 Event detection, e.g. detecting unique waveforms indicative of a medical condition A61B5/4094, A61B5/4818, A61B5/349, A61B5/0823 take precedence
• CPC Class Codes: A61B 5/7465 Arrangements for interactive communication between patient and care services, e.g. by using a telephone network telemetry of measured physiological signal A61B5/0002
• CPC Class Codes: A61N 1/00 Electrotherapy; Circuits therefor A61N2/00 takes precedence; irradiation apparatus A61N5/00
• CPC Class Codes: A61N 1/205 for promoting a biological process
• CPC Class Codes: A61N 1/326 for promoting growth of cells, e.g. bone cells
• CPC Class Codes: A61N 1/36053 adapted for vagal stimulation A61N1/36114 takes precedence
• CPC Class Codes: G16H 20/30 relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16H 50/30 for calculating health indices; for individual health risk assessment

Abstract

Methods and medical device systems for preventing or abating seizures, making use of an association between the probability or likelihood of seizure occurrence and the concentrations or activity levels of one or more of putrescine, spermidine, spermine, or γγ-aminobutyric acid (GABA). The concentration or activity level of putrescine, spermidine, spermine, or GABA, or a substrate or enzyme for synthesis thereof, may be determined, and at least one further action may be performed.

Claims

1. A non-transitory computer readable program storage unit encoded with instructions that, when executed by a computer, perform a method, comprising:

determining at least one of (i) a concentration of at least one polyamine selected from putrescine, spermidine, spermine, or γ

-aminobutyric acid (GABA) in a brain of a patient, (ii) a concentration of a substrate for synthesis of putrescine, spermidine, spermine, or GABA in said brain of said patient, (iii) a concentration or an activity level of an enzyme for synthesis of putrescine, spermidine, spermine, or GABA in said brain of said patient, or (iv) a concentration of a metabolite of one of putrescine, spermidine, spermine, or GABA in said brain of said patient; and

taking a further action selected from;

issuing a warning if said concentration or activity level is below a first reference value;

indicating a lower probability or likelihood of an epileptic event if said concentration or activity level is above a second reference value;

increasing said concentration if said concentration or activity level is below a third reference value;

or

maintaining said concentration or activity level above a fourth reference value.

2. The non-transitory computer readable program storage unit of claim 1, encoded with instructions that, when executed by a computer, perform the method of claim 1, wherein said increasing said concentration of said polyamine comprises activating an endogenous mechanism selected from increasing the concentration of at least one substrate for polyamine synthesis, increasing the activity of ornithine decarboxylase, increasing a concentration of a cofactor of ornithine decarboxylase, or decreasing the degradation of one or more of said polyamines.

3. The non-transitory computer readable program storage unit of claim 1, encoded with instructions that, when executed by a computer, perform the method of claim 1, wherein said increasing said concentration of said polyamine comprises administering at least one of said polyamine to said patient, or an electrical current to a neural tissue of said patient.

4. The non-transitory computer readable program storage unit of claim 3, encoded with instructions that, when executed by a computer, perform the method of claim 3, wherein said neural tissue is selected from a vagus nerve, a cranial nerve other than a vagus nerve, a peripheral nerve, a spinal root, a portion of a spinal cord, or a portion of a brain.

8. The non-transitory computer readable program storage unit of claim 1, encoded with instructions that, when executed by a computer, perform the method of claim 1, wherein the method further comprises determining a probability or likelihood of an occurrence of at least one seizure during a first time window, based on said concentration;

and

taking a second further action selected from;

issuing a warning if said probability or likelihood is above a fifth reference value;

indicating a lower probability or likelihood of an epileptic event if said probability or likelihood is below a sixth reference value;

increasing said concentration if said probability or likelihood is above a seventh reference value;

or

maintaining said concentration if said probability or likelihood is below an eighth reference value.

9. The non-transitory computer readable program storage unit of claim 1, encoded with instructions that, when executed by a computer, perform the method of claim 1, wherein said determining is in response to at least one of a time of day, a state of the epileptogenic network, a state of the brain, a state of the patient, or at least one change in the environment.

5. A non-transitory computer readable program storage unit encoded with instructions that, when executed by a computer, perform a method, comprising:

determining an occurrence of a seizure in a patient;

increasing a concentration of at least one polyamine selected from putrescine, spermidine, spermine, or γ

-aminobutyric acid (GABA) in a brain of said patient, a concentration of a substrate for synthesis of putrescine, spermidine, spermine, or GABA in said brain, or a concentration or an activity level of an enzyme for synthesis of putrescine, spermidine, spermine, or GABA in said brain in response to said determining, within a predetermined time period after the occurrence of said seizure.

6. The non-transitory computer readable program storage unit of claim 5, encoded with instructions that, when executed by a computer, perform the method of claim 5, wherein said increasing said concentration of said polyamine comprises activating an endogenous mechanism selected from increasing the concentration of at least one substrate for polyamine synthesis, increasing the activity of ornithine decarboxylase, increasing a concentration of a cofactor of ornithine decarboxylase, or decreasing the degradation of one or more of said polyamines.

7. The non-transitory computer readable program storage unit of claim 5, encoded with instructions that, when executed by a computer, perform the method of claim 5, wherein said increasing said concentration of said polyamine comprises administering at least one of said polyamine to said patient, or an electrical current to a neural tissue of said patient.

10. A medical device system, comprising:

(i) at least one sensor configured to collect data relating to at least one of;

a concentration of a polyamine selected from putrescine, spermidine, spermine, or γ

-aminobutyric acid (GABA);

a concentration of a substrate for synthesis of putrescine, spermidine, spermine, or GABA;

a concentration of a metabolite of putrescine, spermidine, spermine, or GABA;

or a concentration or an activity level of an enzyme for synthesis of putrescine, spermidine, spermine, or GABA;

in a brain of a patient;

(ii) at least one processor configured to;

(ii-a) determine said concentration or said activity level of said polyamine, said substrate, said metabolite, or said enzyme from said collected data;

(ii-b) perform one or more of;

(ii-b-1) estimate a future concentration or activity level of at least one polyamine, said substrate, said metabolite, or said enzyme;

(ii-b-2) compare said concentration or activity level to a reference value;

or

(ii-b-3) determine, as function of said concentration or activity level, a probability or likelihood of an occurrence of at least one seizure during a first time window; and

(ii-c) issue a signal relating to a further action, based on at least one of said estimated future concentration or activity level, said compared concentration or activity level, or said determined probability or likelihood; and

at least one of;

(iii) a warning unit configured to provide a warning relating to at least one of said estimated future concentration or activity level, said compared concentration or activity level, or said determined probability or likelihood;

(iv) a concentration increasing unit configured to increase said concentration or activity level, based on at least one of said estimated future concentration or activity level, said compared concentration or activity level, or said determined probability or likelihood.

(v) a probability indication unit configured to indicate a lower probability of an epileptic event, based on at least one of said estimated future concentration or activity level, said compared concentration or activity level, or said determined probability or likelihood;

or

(vi) a concentration maintaining unit configured to maintain said concentration or activity level, based on at least one of said estimated future concentration or activity level, said compared concentration or activity level, or said determined probability or likelihood.

11. The medical device system of claim 10, wherein said concentration increasing unit is configured to perform at least one of:

(iv-a) increase the concentration of at least one substrate for polyamine synthesis, (iv-b) increase the activity of ornithine decarboxylase, (iv-c) increase a concentration of a cofactor of ornithine decarboxylase, or (iv-d) decrease the degradation of one or more of said polyamines.

12. The medical device system of claim 10, wherein said concentration increasing unit is configured to:

(iv-c) administer at least one of (iv-c-1) said polyamine to said patient, or (iv-c-2) an electrical current to a neural tissue of said patient.